KRYS - Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory Boards | Benzinga
-- Hubert Chen, accomplished drug developer and pharma executive, joins as Chief Medical Officer
-- Industry veterans and leading academic experts joined Attovia's Clinical and Scientific Advisory Boards: Jonathan Silverberg, M.D., Ph.D., M.P.H., Lawrence Eichenfield, M.D., Brian Kim, M.D., MTR, Sonja Ständer, M.D., Dedee Murrell, M.D., D.Sc., Richard Heyman, Ph.D., Luisa Salter-Cid, Ph.D., and David King, Ph.D.
FREMONT, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the appointment of Hubert Chen, M.D., MPH, as Chief Medical Officer, effective March 21, 2024. Dr. Chen brings extensive clinical and industry leadership experience in drug development and joins Attovia from Krystal Biotech (NASDAQ:KRYS), where he was Senior Vice President of Clinical Development. At Attovia, Dr. Chen will lead the company's clinical development and regulatory functions and will serve on the Executive Committee.
"Hubert's leadership experience, deep expertise in immunology drug development, and successful track record of bringing novel medicines to patients will be invaluable as we continue to advance our portfolio of innovative biotherapeutics and transition to a clinical stage company," said Tao Fu, co-founder and Chief Executive Officer of Attovia. "He will play an integral role in shaping our clinical development strategy as we move our lead product candidates, ATTO-1310 and ATTO-002, toward the clinic, and in building and strengthening our research and development organization."
"I am delighted to join Attovia's leadership team and help unlock the potential of our innovative Attobodies for patients in need of new therapeutic options," said Dr. Chen. "The potential of the Company's Attobody platform combined with its broad and growing pipeline creates a tremendous opportunity to develop novel and potentially transformative therapies across immune-mediated diseases."
At Krystal Biotech, Dr. Chen played an instrumental role in the approval of the first topical gene therapy, Vyjuvek®, for the treatment of dystrophic epidermolysis bullosa. Prior to Krystal, Dr. Chen was at Genentech/Roche where he held clinical leadership positions across both early and late-stage development. As the global development lead for Xolair®, he successfully led the sBLA filing for chronic spontaneous urticaria. During his tenure at Genentech, he also expanded the immunology portfolio by leading the entry of three novel molecules into first-in-human/proof-of-concept trials, including an anti-IL-13 bispecific, and the acquisition of two early-stage clinical assets, which subsequently advanced to later stage trials. Dr. Chen started his career as an Assistant Professor in the Division of Pulmonary and Critical Care at UCSF, where he served as a clinical faculty member for over a decade. He received a medical degree from Stanford and a master of public health degree from Harvard. He completed his post-doctoral residency/fellowship training at Stanford and UCSF. He is board-certified in Internal Medicine, Pulmonary Medicine, ...